Skip to content

Evaluation for effects of DHA regimes in the treatment of refractory/relapse AML and secondary AML patients (Dec+HA for RR –AML and sAML)

Evaluation for effects of DHA regimes in the treatment of refractory/relapse AML and secondary AML patients (Dec+HA for RR –AML and sAML)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016523
Enrollment
Unknown
Registered
2018-06-06
Start date
2018-08-01
Completion date
Unknown
Last updated
2018-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukemia

Interventions

Reinduction:Dec+HA

Sponsors

The First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged 18 years and older; 2. patients diagnosed with MDS were not treated with DTA; 3. IPSS-R classification was low or intermaediate risk; 4. appropriate cardiac function (QTc interval is less than 460 milliseconds); 5. the function of liver and kidney: creatinine less than 2 mg/dl, total bilirubin less than 2 mg/dl, cereal transaminase (AST) less than 2.5 times the normal upper limit (ULN), alanine aminotransferase (ALT) less than 2.5 ULN; 6. sign informed consent.

Exclusion criteria

Exclusion criteria: 1. pregnant women or lactation women; 2. patients with uncontrolled heart failure, unstable angina, arrhythmia or mental disorders; 3. uncontrolled infection disease; 4. HIV infected patients; 5. Patients with 3 or high stage chronic renal disease.

Design outcomes

Primary

MeasureTime frame
remission state of bone marrow;remission state of hematology;disappear of extramedullary invasion;event-free survival;overall survival;cumulative disease rate of relapse;

Secondary

MeasureTime frame
early mortality rate;

Countries

China

Contacts

Public ContactLi Wang

The First Affiliated Hospital of Chongqing Medical University

5640326@qq.com+86 18623015252

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026